BIAF
NASDAQ · Biotechnology
Bioaffinity Technologies Inc
$0.80
-0.03 (-3.18%)
Open$0.83
Previous Close$0.83
Day High$0.84
Day Low$0.80
52W High$13.80
52W Low$0.69
Volume—
Avg Volume879.4K
Market Cap5.21M
P/E Ratio—
EPS$-11.32
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+3,432.9% upside
Current
$0.80
$0.80
Target
$28.39
$28.39
$22.24
$28.39 avg
$33.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 22.50M | 608.9K | 644.1K |
| Net Income | -54,430,150 | -195,635 | -204,930 |
| Profit Margin | -242.0% | -32.1% | -31.8% |
| EBITDA | -36,753,389 | -176,028 | -183,952 |
| Free Cash Flow | — | -119,784 | -113,422 |
| Rev Growth | — | +18.5% | +20.2% |
| Debt/Equity | 0.11 | 1.28 | 1.08 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |